CD4+ T cell immunity is dependent on an intrinsic stem-like program

Recorded on Thursday, July 18, 2024, from 2:00 PM ET to 3:00 PM ET • Sponsored by AST's Community of Transplant Scientists (COTS)

"CD4+ T cell immunity is dependent on an intrinsic stem-like program"
(Nat Immunol. 2024 Jan;25(1):66-76. doi: 10.1038/s41590-023-01682-z. Epub 2024 Jan 2.)

In this article:
CD4+ T cells are central to various immune responses, but the molecular programs that drive and maintain CD4+ T cell immunity are not entirely clear. Here [the authors] identify a stem-like program that governs the CD4+ T cell response in transplantation models... [The authors'] findings unravel a stem-like program that controls the self-renewal capacity and effector differentiation potential of CD4+ TEP cells and have implications for T cell-related immunotherapies.

Speaker:
- Wenhao Chen, PhD • Houston Methodist Hospital, Houston, TX

Moderator:
- Miguel Fribourg, PhD • Icahn School of Medicine at Mount Sinai, New York, NY

Discussant:
- Xian Li, MD, PhD • Houston Methodist Hospital, Houston, TX

Drs. Chen and Li also provided follow-up written responses to several questions submitted during the webinar. These answers can be found here.

Watch Video

Educational Content Disclaimer: The content, information, opinions, and viewpoints contained in educational materials housed on and linked from the AST web site are those of the authors or contributors of such materials. While the AST and its committees take great care to screen the credentials of the contributors and make every attempt to review the contents, AST MAKES NO WARRANTY, EXPRESSED OR IMPLIED, as to the completeness or accuracy of the content contained in the educational materials or on this website. The reader of these materials uses these materials at his or her own risk, and AST shall not be responsible for any errors, omissions, or inaccuracies in these materials, whether arising through negligence, oversight, or otherwise. Reliance on any information appearing on this site is strictly at your own risk. Read the full disclaimer.